Related Experiment Video
Updated: May 7, 2026
08:11
Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
Colchicine and the heart: pushing the envelope
Spyridon Deftereos1, Georgios Giannopoulos, Nikolaos Papoutsidakis
1Department of Cardiology, Athens General Hospital "G. Gennimatas", Athens, Greece; Section of Cardiovascular Medicine, Yale University School of Medicine, Yale University, New Haven, Connecticut.
Journal of the American College of Cardiology
|September 17, 2013
Summary
Colchicine, an ancient anti-inflammatory drug, inhibits microtubule polymerization. Emerging research highlights its potential cardiovascular benefits beyond traditional uses like gout and pericarditis.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Cell Biology
Background:
- Colchicine is an established treatment for gout, pericarditis, familial Mediterranean fever, and Behcet's disease.
- Its anti-inflammatory classification is based on effects beyond the arachidonic acid pathway.
- Colchicine's mechanism involves inhibiting microtubule polymerization via tubulin binding.
Purpose of the Study:
- To review the biochemical characteristics, mechanism of action, and side effects of colchicine.
- To explore the emerging role of colchicine in cardiovascular medicine.
- To examine current knowledge on colchicine's cardiovascular applications beyond pericardial disease.
Main Methods:
- Literature review of colchicine's pharmacology.
- Analysis of studies investigating colchicine's mechanism of action.
- Synthesis of research on colchicine's therapeutic potential in cardiovascular diseases.
Main Results:
- Colchicine inhibits microtubule polymerization, impacting cellular processes like mitosis and neutrophil motility.
- Recent studies indicate potential efficacy in a broader range of cardiovascular conditions.
- The drug's established anti-inflammatory properties are being re-evaluated for cardiovascular indications.
Conclusions:
- Colchicine's unique mechanism of action warrants further investigation in cardiovascular medicine.
- The drug shows promise for treating cardiovascular diseases beyond its traditional indications.
- Continued research may expand colchicine's therapeutic applications in cardiology.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:17Pericarditis III: Medical Management
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...